A novel machine learning based framework for developing composite digital biomarkers of disease progression.

Journal: Frontiers in digital health
Published Date:

Abstract

BACKGROUND: Current methods of measuring disease progression of neurodegenerative disorders, including Parkinson's disease (PD), largely rely on composite clinical rating scales, which are prone to subjective biases and lack the sensitivity to detect progression signals in a timely manner. Digital health technology (DHT)-derived measures offer potential solutions to provide objective, precise, and sensitive measures that address these limitations. However, the complexity of DHT datasets and the potential to derive numerous digital features that were not previously possible to measure pose challenges, including in selection of the most important digital features and construction of composite digital biomarkers.

Authors

  • Song Zhai
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Andy Liaw
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Judong Shen
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Yuting Xu
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Vladimir Svetnik
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • James J FitzGerald
    NeuroMetrology Lab, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • Chrystalina A Antoniades
    NeuroMetrology Lab, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • Dan Holder
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Marissa F Dockendorf
    Digital Clinical Measures, Translational Medicine, Merck & Co., Inc., Rahway, NJ, United States.
  • Jie Ren
    Digital Clinical Measures, Translational Medicine, Merck & Co., Inc., Rahway, NJ, United States.
  • Richard Baumgartner
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.

Keywords

No keywords available for this article.